Last update 24 May 2025

JNJ-90014496

Overview

Basic Info

Drug Type
CAR-T
Synonyms
JNJ-90014496
Target
CD19 x CD20
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Diffuse Large B-Cell LymphomaHigh grade B-cell lymphomaRefractory Mature B-Cell Non-Hodgkin Lymphoma
Inactive Indication-
Originator Organization
Janssen Research & Development LLC
Active Organization
Janssen Research & Development LLC
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with JNJ-90014496
NCT05421663
/ RecruitingPhase 1
A Phase 1b Multicenter, Open-Label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-Cell Non-Hodgkin Lymphoma
100 Clinical Results associated with JNJ-90014496
Login to view more data
100 Translational Medicine associated with JNJ-90014496
Login to view more data
100 Patents (Medical) associated with JNJ-90014496
Login to view more data
100 Deals associated with JNJ-90014496
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 1
United States
Janssen Research & Development LLC
12 Aug 2022
Diffuse Large B-Cell LymphomaPhase 1
Australia
Janssen Research & Development LLC
12 Aug 2022
Diffuse Large B-Cell LymphomaPhase 1
Canada
Janssen Research & Development LLC
12 Aug 2022
Diffuse Large B-Cell LymphomaPhase 1
Denmark
Janssen Research & Development LLC
12 Aug 2022
Diffuse Large B-Cell LymphomaPhase 1
Netherlands
Janssen Research & Development LLC
12 Aug 2022
Diffuse Large B-Cell LymphomaPhase 1
Spain
Janssen Research & Development LLC
12 Aug 2022
Diffuse Large B-Cell LymphomaPhase 1
United Kingdom
Janssen Research & Development LLC
12 Aug 2022
High grade B-cell lymphomaPhase 1
United States
Janssen Research & Development LLC
12 Aug 2022
High grade B-cell lymphomaPhase 1
Australia
Janssen Research & Development LLC
12 Aug 2022
High grade B-cell lymphomaPhase 1
Canada
Janssen Research & Development LLC
12 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free